Liposomes are small spherical vesicles composed of an aqueous core encircled by one or several bilayers of natural or synthetic lipids. They are increasingly used as drug delivery vehicles due to their ability to encapsulate both hydrophilic and hydrophobic therapeutic agents, protecting them from degradation and thereby enhancing their bioavailability. Successful drug delivery relies on both the type of liposome used and the method of administration. Aerosol administration of liposomes presents a promising technique for localized drug delivery, particularly in respiratory disorders.
In aerosol administration of liposomes, a drug encapsulated within liposomes is delivered as an aerosol. This involves the conversion of the drug-liposome formulation into small inhaled particles using a nebulizer or a pressurized metered-dose inhaler (pMDI). Once inhaled, these particles are designed to deposit in the targeted areas of the respiratory tract, usually the deep lung tissues. Here, the liposomes slowly release the encapsulated drug over an extended period, which effectively retains the drug within the lungs, prolonging its therapeutic effects and enhancing its bioavailability.
Liposomes used in aerosol administration are broadly classified into conventional liposomes and long-circulating liposomes. Conventional liposomes are typically composed of natural or synthetic phospholipids and cholesterol. They encapsulate the drug within the aqueous core or the lipid bilayers and release the drug through fusion with the cell membrane, subsequent enzymatic degradation of the liposome, or passive diffusion.
On the other hand, long-circulating liposomes, also known as sterically stabilized or 'stealth' liposomes, possess an extended circulation time due to the presence of a hydrophilic polymeric shield, typically composed of polyethylene glycol (PEG), on their surface. This modification imparts steric stability to the liposomes, protecting them from detection and clearance by the body's immune system, and thus enabling extended drug release.
The aerosol administration of liposomes finds varied applications in the field of medicine, predominantly in the treatment of respiratory diseases. It is an effective method of delivering anti-inflammatory and anti-fibrotic agents to treat chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). It is also used in delivering antibiotics for treating lung infections, anticancer agents for lung cancer, and gene therapy agents for cystic fibrosis.
Aerosol administration of liposomes offers several benefits over traditional systemic administration methods. Firstly, it allows for targeted and localized drug delivery, resulting in enhanced bioavailability and reduced systemic side-effects. Secondly, liposomes as drug carriers provide sustained drug release, leading to prolonged therapeutic effects and reduced frequency of administration. Moreover, the aerosol administration route is non-invasive, leading to increased patient compliance. Also, liposomes protect the encapsulated drug from enzymatic and hydrolytic degradation, enhancing the stability and lifespan of the drug. This method can be tailored to deliver a wide range of therapeutic agents, rendering it flexible and versatile.
Aerosol administration of liposomes holds immense potential as a drug delivery system. While there's ongoing research in optimizing liposome formulations for aerosol delivery, the current applications and benefits underline the substantial promise in this emerging field within respiratory medicine.
Creative Biolabs provides custom liposomal services and products. If you are interested, do not hesitate to contact us for more information.
For Research Use Only. Not For Clinical UseSupports
Online Inquiry
Creative Biolabs is a world-leading liposome provider with extensive experience in liposome preparation, custom formulation development, and characterization.
© 2026 Creative Biolabs. All rights reserved.